FX.co ★ Takeda Signs Manufacturing Partnership With India's Biological E. For Dengue Vaccine QDENGA

Late Monday, Takeda Pharmaceutical announced a strategic manufacturing partnership with Indian vaccine and pharmaceutical company, Biological E. Ltd. This partnership is aimed at increasing accessibility to TAK-003, a dengue vaccine also known as QDENGA, which Takeda has developed. QDENGA, based on a live-attenuated dengue serotype 2 virus, contains the genetic "backbone" for all four dengue virus serotypes and is designed to protect against any of these serotypes.

Under the terms of this partnership, Biological E. will boost its manufacturing capacity to produce up to 50 million doses annually. This output aligns with Takeda’s goal to manufacture 100 million doses of the vaccine yearly by 2030 at the latest.

Takeda will build on its current vaccine manufacturing capacity, based in Singen, Germany, and its long-term partnership with IDT Biologika GmbH. The company announced that by 2030, these doses will be available for purchase by governments in regions where the disease is endemic. Multi-dose vials, or MDVs, offer economic and logistical advantages as they minimize packaging and storage costs, as well as medical and environmental waste.

QDENGA is presently available for children and adults in Europe's private market, Indonesia, and Thailand, as well as in private and select public programs in Argentina and Brazil. However, TAK-003 is not approved for use in India. For more health-related news, visit rttnews.com.